OpenScience.ink

3 weeks ago • Hormone research in paediatrics

Keeping Weight Stable After Stopping Semaglutide in a Teen with Weight Gain from Antipsychotic Medication: A Case ReportWeight Maintenance Following Discontinuation of Semaglutide in an Adolescent with Antipsychotic-Associated Weight Gain: A Case Report.

📖 Top 20% JournalCase Reports

3 weeks ago • American journal of clinical pathology

Tirzepatide may cause rare but serious air pockets in the intestinesTirzepatide-induced pneumatosis intestinalis: a rare but clinically significant gastrointestinal adverse effect.

📖 Top 30% JournalCase Reports

5 days ago • CNS spectrums

Differences between men and women in glucagon-like peptide-1 signaling and what it may mean for Alzheimer's diseaseSex differences in glucagon-like peptide-1 signalling and the implications for Alzheimer's disease: A narrative review.

📖 Top 20% JournalArticle

1 week ago • Medicina (Kaunas, Lithuania)

The Role of Stomach Balloons Compared to New Effective Obesity MedicinesDo Gastric Balloons Have a Future? Intragastric Balloons in the Era of Highly Effective Obesity Pharmacotherapy.

📖 Top 30% JournalArticle

1 week ago • Metabolites

Weight gain after stopping GLP-1 and GIP/GLP-1 hormone treatments: A systematic reviewWeight Regain After Discontinuation of GLP-1 and GIP/GLP-1 Receptor Agonists: A Systematic Review.

📖 Top 20% JournalArticle

1 week ago • Genes

How Gene Activity Patterns Link Exenatide Treatment to Aging Signs in Immune Cells in Colorectal CancerSignature Definition Shapes Associations Between Exenatide-Related Transcriptional Programs and Macrophage Senescence Scores in Colorectal Cancer.

📖 Top 20% JournalArticle

1 week ago • Journal of personalized medicine

Current Understanding and Future Outlook of Semaglutide in Irregular HeartbeatsSemaglutide in Atrial Arrhythmias: State of the Art and Future Perspectives.

📖 Top 20% JournalArticle

1 week ago • Diseases (Basel, Switzerland)

Common Medication Use and Remaining Heart and Metabolic Risks in People with Type 2 Diabetes in RomaniaReal-World Pharmacological Patterns and Residual Cardiometabolic Risk in Patients with Type 2 Diabetes in Romania.

📖 Top 20% JournalArticle

2 weeks ago • Healthcare (Basel, Switzerland)

Weight, safety, and usage of GLP-1 and combined GIP/GLP-1 treatments in obesity and blood sugar disorders across community pharmaciesReal-World Anthropometric Outcomes, Safety, and Use Patterns of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Obesity and Glucose Metabolism Disorder: A Nationwide Multicentre Community Pharmacy Study.

📖 Top 30% JournalArticle

3 weeks ago • Journal of the Endocrine Society

Glucagon-like peptide 1 receptor drugs and their possible link to sudden optic nerve damageCurrent review of glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathy.

📖 Top 20% JournalArticle

3 weeks ago • Journal of diabetes

Use and Costs of Diabetes Drugs That Activate GLP-1 from 2008 to 2023Diabetes Medication Market: Costs and Utilization of Glucagon-Like Peptide 1 (GLP-1) Prescriptions From 2008 to 2023.

📖 Top 20% JournalLetter

3 weeks ago • Obesity science & practice

What Patients Know About Weight-Loss Drugs and How They Might Affect Their Households in a City Health SystemPatient Knowledge of GLP-1 Receptor Agonists for Obesity and Exploration of Potential Household-Level Effects in an Urban Health System.

📖 Top 30% JournalArticle

3 weeks ago • Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery

Incretin’s role in type 2 diabetes remission after gastric bypass surgeryIncretin influence on type 2 diabetes mellitus remission after Roux-en-Y gastric bypass.

📖 Top 50% JournalArticle

yesterday • Annals of human biology

How GLP-1 receptor drugs relate to the rise of obesity, inactivity, and loneliness from an evolutionary viewEvolutionary perspectives on GLP-1 receptor agonists and the modern obesity, sedentary behaviour, and loneliness epidemics.

📖 Top 50% JournalArticle

yesterday • Diabetology international

Monocyte GIP receptor levels linked to weight loss and liver health improvements after switching to tirzepatide in type 2 diabetes patientsBaseline monocyte GIP receptor mRNA expression is associated with reductions in body weight and FIB-4 index after switching to tirzepatide in patients with type 2 diabetes.

📖 Top 50% JournalArticle

yesterday • Cardiology in the young

Patient outcomes with incretin-based drugs and SGLT2 inhibitors in obesity-related heart failure with preserved heart pumpingPatient-centred outcomes with incretin-based therapies and sodium-glucose cotransporter 2 inhibitors in obesity-related heart failure with preserved ejection fraction: a programme-level systematic review and meta-analysis.

📖 Top 50% JournalArticle

yesterday • Journal of health care for the poor and underserved

Medicaid Coverage Rules and Real-World Challenges in Getting TirzepatideCoverage Criteria vs. Clinical Reality: Navigating Medicaid Barriers to Tirzepatide Access.

📖 Top 30% JournalCase Reports

yesterday • The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry

How Drugs Acting on GLP-1 Receptors May Affect Thinking About FoodGLP-1 Receptor Agonist Effects on Food-Related Cognition: A Cognitive Neuroscience Framework.

🎖️ Top 10% JournalArticle

yesterday • Annals of internal medicine

In Type 2 Diabetes, Using Both SGLT2 Inhibitors and GLP-1 Receptor Agonists Together Does Not Lower Major Heart or Kidney Problems Compared to Using Either One AloneIn T2D, combined SGLT2i + GLP-1 RA vs. either alone does not reduce MACE or renal outcomes.

🥈 Top 2% JournalArticle

yesterday • Molecular pharmaceutics

Imaging of a drug targeting both GLP-1 and GIP receptors using a radioactive tracerPET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide.

📖 Top 20% JournalArticle

2 days ago • International journal of biological macromolecules

Design and testing of a long-lasting GLP-1 drug linked to albumin: structure, receptor activation, and functionDevelopment of an albumin-binding domain-fused GLP-1 analog: Structural insights, receptor activation, and functional characterization.

📖 Top 20% JournalArticle

2 days ago • Kidney research and clinical practice

Effects of combining two diabetes medications on people with chronic kidney disease in real-world settingsEffect of combined sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonist therapy in patients with chronic kidney disease: a real-world analysis.

📖 Top 20% JournalArticle

3 days ago • Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

GLP-1 receptor agonist treatment linked to heart health in patients with fatty liver diseaseAssociation of GLP-1 receptor agonist therapy with cardiovascular outcomes in patients with MASLD: A translational study.

🎖️ Top 10% JournalArticle

3 days ago • Gynecologic oncology

Use of diabetes drugs that reduce appetite in obese patients with uterine cancer over timeTrends in use of glucagon-like peptide-1 receptor agonists in obese patients with endometrial cancer.

🎖️ Top 10% JournalArticle

3 days ago • Molecular metabolism

Removing GIP receptors from excitatory brain cells does not stop GIP receptor blockers from speeding up weight loss caused by GLP-1Loss of GIPR in glutamatergic neurons does not impair acceleration of GLP-1-induced weight loss by GIPR antagonism.

🥉 Top 5% JournalArticle

3 days ago • Journal of translational medicine

Gut bacteria-produced butyrate may improve blood sugar control during pregnancy by activating hormone pathways through gene regulationThe gut microbiota-derived butyrate improves gestational glucose homeostasis through HDAC3 inhibition and epigenetic activation of the SCGN/GLP-1 axis.

🥉 Top 5% JournalArticle

3 days ago • Body image

How social influences relate to women's consideration of GLP-1 medication in the UKA test of the Tripartite Influence Model in the context of GLP-1 medication consideration among women in the United Kingdom.

🥉 Top 5% JournalArticle

3 days ago • Molecular metabolism

Targeting a specific stress-related receptor reduces fat, builds muscle, and improves blood sugar control in early obesityDifferentiated obesity treatment: Pharmacological CRF2 agonism drives fat loss, skeletal muscle hypertrophy and improved glucose metabolism in preclinical obesity.

🥉 Top 5% JournalArticle

4 days ago • Clinical kidney journal

Using one or several nutritional hormone receptor treatments for chronic kidney diseaseSingle or multiple nutritional hormone receptor modulators for chronic kidney disease.

🎖️ Top 10% JournalArticle

4 days ago • The lancet. Diabetes & endocrinology

Effectiveness and safety of oral orforglipron in Japanese people with obesityEfficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial.

🥇 Top 1% JournalArticle

← prevpage 5 of 16next →

GLP-1 Therapies Research Papers